Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 165 | 31 | 131 |
| Samples | 87 | 19 | 66 |
| Peptides | 77 | 12 | 63 |
Function
GFER · Growth factor, augmenter of liver regeneration
The hepatotrophic factor designated augmenter of liver regeneration (ALR) is thought to be one of the factors responsible for the extraordinary regenerative capacity of mammalian liver. It has also been called hepatic regenerative stimulation substance (HSS). The gene resides on chromosome 16 in the interval containing the locus for polycystic kidney disease (PKD1). The putative gene product is 42% similar to the scERV1 protein of yeast. The yeast scERV1 gene had been found to be essential for oxidative phosphorylation, the maintenance of mitochondrial genomes, and the cell division cycle. The human gene is both the structural and functional homolog of the yeast scERV1 gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 64 amino-acid changes on canonical ENST00000248114 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GFER · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GFER – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 7/1592 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 8/1390 1% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Melanoma | 1/210 0% | 8/1899 0% |
| Biliary Tract Carcinoma | 1/54 2% | 3/950 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Esophageal Carcinoma | 2/23 9% | 1/769 0% |
| Gastric Carcinoma | 2/74 3% | 5/1809 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 2/810 0% |
| Colorectal Carcinoma | 3/143 2% | 7/3239 0% |
| Glioma | 1/52 2% | 5/2127 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Endometrial Carcinoma | 0/42 0% | 1/612 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Other Sarcomas | 1/69 1% | 0/699 0% |
| Other Solid Cancers | 0/94 0% | 2/1515 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Ovarian Carcinoma | 1/109 1% | 0/998 0% |
| Hepatocellular Carcinoma | 0/46 0% | 2/2210 0% |
| Head and Neck Carcinoma | 0/85 0% | 1/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Breast Carcinoma | 0/144 0% | 2/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
Mutation Distribution
Where GFER is mutated · all tissues, split by cell line vs tissue
How many mutations in GFER were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 165 mutations in GFER
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|